Seribantumab- Merrimack Pharmaceuticals

Drug Profile

Seribantumab- Merrimack Pharmaceuticals

Alternative Names: MM-121; SAR-256212

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merrimack Pharmaceuticals
  • Developer Merrimack Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase I Gynaecological cancer; Solid tumours

Most Recent Events

  • 30 Oct 2017 Seribantumab receives Orphan Drug status for Non-small cell lung cancer in USA
  • 13 Sep 2017 Seribantumab is still in phase II trials for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT02387216)
  • 31 Aug 2017 Merrimack Pharmaceuticals terminates a phase I trial due to internal decision in Solid tumours (Late-stage disease, Combination therapy) in USA (Parenteral) (NCT02538627)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top